ArticleScientific reports2026
Applying ensemble machine learning techniques to MRI scans to predict Alzheimer's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia globally. Early prediction, prior to the onset of symptoms, is critical for enabling timely interventions. We present a machine learning framework that predicts future AD conversion in cognitively normal (CN) individuals using only structural magnetic resonance imaging (MRI) data. The approach leverages transfer learning with a pre-trained VGG16 model for feature extraction and processes five representative 2D slices per brain MRI scan to generate compact imaging descriptors. These features are classified using an ensemble composed of support vector machines (SVM), random forests (RF), and artificial neural networks (ANN), with outputs combined through soft voting. The model was evaluated using person-wise stratified cross-validation on 1,093 subjects from the OASIS-3 dataset, ensuring no data leakage and providing realistic performance estimates. Across 200 randomized runs, the ensemble achieved a median AUC-ROC of 0.951, accuracy of 0.872, recall of 0.923, and F1 score of 0.811. These results demonstrate that ensemble machine learning can detect preclinical AD signatures from structural MRI, offering a practical, relatively accessible, and cost-effective tool for early risk identification and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.